Publications dans lesquelles il/elle collabore avec Luis Miguel Blanco Colio (17)

2018

  1. Lipocalin-2, a potential therapeutic target in advanced atherosclerosis

    Atherosclerosis

2016

  1. Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice

    Cardiovascular Research, Vol. 111, Núm. 3, pp. 262-273

2014

  1. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice

    Journal of Cellular and Molecular Medicine, Vol. 18, Núm. 4, pp. 721-734

2013

  1. Proteomic analysis of intraluminal thrombus highlights complement activation in human abdominal aortic aneurysms

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 33, Núm. 8, pp. 2013-2020

2012

  1. Plasma profiling by a protein array approach identifies IGFBP-1 as a novel biomarker of abdominal aortic aneurysm

    Atherosclerosis, Vol. 221, Núm. 2, pp. 544-550

2011

  1. Animal models of cardiovascular diseases

    Journal of Biomedicine and Biotechnology, Vol. 2011

2009

  1. Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis

    Cardiovascular Research, Vol. 81, Núm. 1, pp. 216-225

2008

  1. Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.

    American Journal of Cardiology, Vol. 102, Núm. 1, pp. 12-18

2006

  1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

    Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69

  2. El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana

    Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 1, pp. 18-23

  3. Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB

    Atherosclerosis, Vol. 187, Núm. 1, pp. 139-149

2005

  1. HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells

    Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475

  2. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800

2004

  1. Estatinas, inflamación y lesión aterosclerótica

    Nefrologia, Vol. 24, Núm. SUPPL.4, pp. 17-20

  2. NF-κB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients with Carotid Atherosclerosis: Potential Implication in Plaque Instability

    Stroke, Vol. 35, Núm. 2, pp. 458-463

  3. Propiedades anti-inflamatorias e inmunomoduladoras de las estatinas

    Nefrologia, Vol. 24, Núm. SUPPL.1, pp. 48-49

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58